Level C· Early human research exploring benefitsProspective StudyPubMed

Metformin Promotes Osteogenic Differentiation of Adipose-Derived Stem Cells in Diabetic Osteoporosis by Regulating Autophagy.

Cao H., Li Q., Gao Y., Li J., Yu P., Lan X.

Prospective Study on Face & Skin, Systemic / IV, published in Cell Biol Int (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cell Biol Int (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40631901
DOI
10.1002/cbin.70061

Abstract (original English)

Patients with diabetic osteoporosis (DOP) face significant challenges in bone defect repair and regeneration. Adipose-derived stem cells (ASCs) have been widely used in bone tissue engineering due to their accessibility and multi-potency. However, DOP-ASCs exhibit lower capacity for osteogenic differentiation compared to control ASCs (CON-ASCs). In this study, we explored the effects of metformin (Met) on the autophagy and osteogenic capacity of DOP-ASCs. DOP mouse model was established with a high-fat and high-glucose diet combined with streptozotocin injection. After treating DOP-ASCs with Met and 3-methyladenine (3-MA), changes in autophagy levels and osteogenic differentiation capacity were observed by western blot analysis, real-time quantitative PCR (qPCR), immunofluorescence, alkaline phosphatase staining, alizarin red staining, and GFP-LC3 fluorescence labeling analysis. DOP-ASCs were cocultured with the Biphasic Calcium Phosphate (BCP), and implanted into the cranial defect area of DOP mice. The mice then received oral Met and intraperitoneal 3-MA injections for 3 months. The implanted BCP was assessed by micro-CT, HE and Masson staining. We observed a significantly reduced autophagic levels and capacity for osteogenic differentiation in DOP-ASCs, as compared to CON-ASCs. Met activated autophagy in DOP-ASCs and improved their osteogenic differentiation capacity. Howeve

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
MetforminAnimalsAutophagyOsteogenesisCell DifferentiationMiceOsteoporosisAdipose TissueStem CellsMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research